Chronic Kidney Disease Improvement in Research and Treatment Act of 2023

Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860/S. 5018, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 10545, American Relief Act, 2025

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 S. 4469, A bill to improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes S. 4510 - The Kidney Patient Act Issues related to patient access to infection prevention.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Assist client with legislation re: Kidney Patient Act; monitor legislation re: same. HR 5074-Kidney PATIENT Act of 2023; S 4510 Kidney PATIENT Act of 2024; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024. HR 6790 New "Era of Preventing End-Stage Kidney Disease Act; HR 5027-S4469 Kidney Disease Improvement in Research and Treatment Act of 2024.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,060,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,060,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; CMS 1782, CY 2024 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment Systems (PPS) and Quality Incentive Program (QIP) proposed rule; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074 Kidney Patient Act of 2024, issues related to CY 2025 CMS final rule for ESRD PPS and Quality Improvement Program.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; CMS 1782, CY 2024 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment Systems (PPS) and Quality Incentive Program (QIP) proposed rule; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074 Kidney Patient Act of 2024, issues related to CY 2025 CMS final rule for ESRD PPS and Quality Improvement Program.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Living Donor Protection Act (H.R. 2923 / S. 1384) Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027/S.4469) Honor Our Living Donors Act (H.R. 6020) Medigap Expansion Act Restore Protections for Dialysis Patients Act (H.R. 6860, S.5081) Expressing support for the designation of the last Tuesday of April each year as "APOL1-Mediated Kidney Disease (AMKD) Awareness Day" (H.Res.1124) Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 (H.R. 5074, S. 4510) PASTEUR Act (H.R. 2940/S. 1355) Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2023 The Access to Genetic Counselor Services Act of 2023 (H.R. 3876/S. 2323) The CARING for Social Determinants Act of 2023 (H.R. 1066) End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model

Client expense: $140,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.6860/ S. 5018 Restore Protections for Dialysis Patients Act H.R. 5074/S. 4510, Kidney Patient Act of 2023 H.R. 8594 - Restore Protections for Dialysis Patients Act, all provisions S. 4750 - Restore Protections for Dialysis Patients Act, all provisions H.R.5027 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2023

Client expense: $1,500,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

Urge Congress to provide access to Medigap for all ESRD patients under 65 years of age; Protect organ donors by urging passage of the living donor legislation; Protect dialysis patient access to charitable premium assistance; Support ESRD care coordination; Encourage support for improved kidney research and treatment; Support increased oversight of Organ Procurement Organizations; Support H.R. 5027/S. 4469 the Chronic Kidney Disease Improvement in Research and Treatment Act; Assist the Administration about prioritizing prevention of kidney disease and home dialysis; Support H.R. 6860/S. 5018 - The Restore Protections for Dialysis Patients Act to protect access to private insurance; Urge the Administration to provide adequate reimbursement to address the ongoing staffing shortages at dialysis centers; and Urge the Administration to provide appropriate reimbursement to increase dialysis patient access to new and innovative therapies. Support efforts to delay moving Xphozah into the ESRD bundle.

Client expense: $250,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, White House Office

FY 25 Congressional appropriations: -Increase funding for Health Resources and Services Administration (HRSA) Organ Transplantation Program -Increase NIH funds, including proportional increase for NIDDK to support kidney research -Provide $25 million to KidneyX to continue development of an artificial kidney and other innovations innovative kidney therapeutics and technologies -Support CDC Chronic Kidney Disease Initiative -Increase funding Veterans Health Administration Kidney Health Program -Address the implementation of the retrospective trend adjustment in the CKCC model Legislation: Explore the establishment of an Officer of Kidney Health and Transplantation at HHS Support implementation of the Securing the U.S. Organ Procurement and Transplantation Act (H.R. 2544/S. 1668), including clarifying HRSA's ability to use OPTN patient waitlist registration fees Increase support for living donors including through the Honor Our Living Donors Act, The Living Organ Donor Tax Credit Act (H.R. 6171), and the Living Donor Protection Act (H.R. 2923/S. 1384) Increase patient choice by passing the Kidney PATIENT Act (H.R. 5074), the Restore Protections for Dialysis Patients Act (H.R. 6860), the Chronic Kidney Disease Research and Treatment Act, (H.R. 5027/S. 4469), and the Providing Relief and Stability for Medicare Patients Act of 2023 (H.R. 3674) Bolster the kidney health care workforce, including by passing the Healthcare Workforce Resilience Act (H.R. 6205/S. 3211), the Strengthening Medicare for Patients and Providers Act (HR 2474), The Specialty Physicians Advancing Rural Care Act (S. 705/ H.R. 2761), and the Resident Physician Shortage Act (HR 2389/S. 1302) Regulatory: Increase kidney health coordination, innovation, and reimbursement through ESRD PPS/QIP, PFS, and ESRD-QIP Measure Set Review Improve transparency and accountability in transplant system to maximize access to kidney transplant, including through the HRSA OPTN Modernization Initiative Establish a federal screening recommendation for kidney diseases

Client expense: $90,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

Kidney care reimbursement; ESRD PPS for CY 2025; Medicare Advantage Rate Announcement; Medicare Advantage 2025 Proposed Rule; ESRD quality programs; transplant issues; home dialysis; H.R. 5027 "Chronic Kidney Disease Improvement in Research and Treatment Act of 2023"; S 4469 the "Chronic Kidney Disease Improvement in Research and Treatment Act of 2024"; ESRD Treatment Choices model; CKCC models; IOTA proposed rule.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE

Kidney Care reimbursement issues; ESRD PPS; Medicare Secondary Payer; ESRD quality programs; HR 5027 Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; S 4469 the Chronic Kidney Disease Improvement in Research and Treatment Act of 2024; ESRD PPS proposed rulemaking CY 2025; Medicare Advantage Rate Announcement; Medicare Advantage FY25 proposed rule

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC)

H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Client expense: $280,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 S. 4469, A bill to improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes S. 4510 - The Kidney Patient Act Issues related to patient access to infection prevention.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Urge Congress to provide access to Medigap for all ESRD patients under 65 years of age; Protect organ donors by urging passage of the living donor legislation; Protect dialysis patient access to charitable premium assistance; Support ESRD care coordination; Encourage support for improved kidney research and treatment; Support increased oversight of Organ Procurement Organizations; Support H.R. 5027/S. 4469 the Chronic Kidney Disease Improvement in Research and Treatment Act; Assist the Administration about prioritizing prevention of kidney disease and home dialysis; Support H.R. 6860/S. 5018 - The Restore Protections for Dialysis Patients Act to protect access to private insurance; Urge the Administration to provide adequate reimbursement to address the ongoing staffing shortages at dialysis centers; and Urge the Administration to provide appropriate reimbursement to increase dialysis patient access to new and innovative therapies. Support efforts to delay moving Xphozah into the ESRD bundle.

Client expense: $500,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, White House Office

Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing End-Stage Renal Disease (ESRD) functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23)

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860/S. 5018, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; CMS 1782, CY 2024 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment Systems (PPS) and Quality Incentive Program (QIP) proposed rule; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074 Kidney Patient Act of 2024

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; CMS 1782, CY 2024 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment Systems (PPS) and Quality Incentive Program (QIP) proposed rule; H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act; H.R. 5074 Kidney Patient Act of 2024

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.6860/ S. 5018 - Restore Protections for Dialysis Patients Act H.R.5074/ S.4510 - Kidney PATIENT Act of 2023 H.R.5027 - Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 Veterans Affairs dialysis services

Client expense: $1,320,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)

Living Donor Protection Act (H.R. 2923 / S. 1384) Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027/S.4469) Honor Our Living Donors Act (H.R. 6020) Medigap Expansion Act Restore Protections for Dialysis Patients Act (H.R. 6860, S.5081) Expressing support for the designation of the last Tuesday of April each year as "APOL1-Mediated Kidney Disease (AMKD) Awareness Day" (H.Res.1124) Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 (H.R. 5074, S. 4510) PASTEUR Act (H.R. 2940/S. 1355) Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2023 The Access to Genetic Counselor Services Act of 2023 (H.R. 3876/S. 2323) The CARING for Social Determinants Act of 2023 (H.R. 1066) End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model

Client expense: $185,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,080,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6860/S. 5018, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,080,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027/S. 4469 - The Kidney Disease Improvement in Research and Treatment Act H.R. 6860/S. 5018 - Restore Protections for Dialysis Patients Act H.R. 5074/S. 4510 - Kidney PATIENT Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Treat and Reduce Obesity Act (H.R. 4818 / S. 4207) Home dialysis/home therapies issues Improving Access to Dialysis Act (H.R. 8075) Living Donor Protection Act (H.R. 2923/S. 1384) FY 2025 appropriations funding for nursing workforce development programs and National Institute of Nursing Research FY 2025 funding kidney disease research at NIDDK at NIH Funding for Kidney X program at HHS Funding for AHRQ at HHS in FY 2025 Securing the U.S. Organ Procurement and Transplantation Network Act (H.R. 2544/S. 1668) National Nursing Workforce Center Act (H.R. 2411/S. 1150) Workplace Violence Prevention for Health Care and Social Service Workers Act (H.R. 2663/S. 1176) Living Donor Protection Act (H.R. 2923/S. 1384) Chronic Kidney Disease Improvement in Research and Treatment Act (H.R. 5027) Kidney Patient Access to Technology Innovative and Essential Nephrology Treatments (Kidney Patient) Act (H.R. 5074) Restore Protections for Dialysis Patients Act (H.R. 6860) Living Organ Donor Tax Credit Act (H.R. 6171) Honor Our Living Donors Act (H.R. 6020) Healthcare Workforce Resilience Act (H.R. 6205 / S. 3211) Restore Protections for Dialysis Patients Act (H.R. 6860) Future Advancement of Academic Nursing Act (H.R. 7266 / S. 3770) Organ Donation Referral Improvement Act (H.R. 9939)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Restore Protections for Dialysis Patients Act & Medigap (H.R. 6860/S. 501) Chronic Kidney Disease Improvement in Research and Treatment Act (H.R. 5027 / S. 4469)

Client expense: Not reported · Firm income: Not reported

Restore Protections for Dialysis Patients Act & Medigap (H.R. 6860/S. 501) Chronic Kidney Disease Improvement in Research and Treatment Act (H.R. 5027 / S. 4469)

Client expense: Not reported · Firm income: Not reported

Kidney care reimbursement; ESRD PPS for CY 2025; Medicare Advantage Rate Announcement; Medicare Advantage 2025 Proposed Rule; ESRD quality programs; transplant issues; home dialysis; H.R. 5027 "Chronic Kidney Disease Improvement in Research and Treatment Act of 2023"; ESRD Treatment Choices model; CKCC models

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE

Kidney Care reimbursement issues; ESRD PPS; Medicare Secondary Payer; ESRD quality programs; HR 5027 Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; ESRD PPS proposed rulemaking CY 2025; Medicare Advantage Rate Announcement; Medicare Advantage FY25 proposed rule

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC)

FY 24 and FY 25 Congressional appropriations: -Increase funding for Health Resources and Services Administration (HRSA) Organ Transplantation Program -Increase NIH funds, including proportional increase for NIDDK to support kidney research and $150 million for a Special Statutory Funding Program for Kidney Research -Provide $25 million to KidneyX to continue development of an artificial kidney and other innovations innovative kidney therapeutics and technologies -Support CDC Chronic Kidney Disease Initiative -Increase funding Veterans Health Administration Kidney Health Program -Address the implementation of the retrospective trend adjustment in the CKCC model Legislation: Explore the establishment of an Officer of Kidney Health and Transplantation at HHS Support implementation of the Securing the U.S. Organ Procurement and Transplantation Act (H.R. 2544/S. 1668) Increase support for living donors including through the Honor Our Living Donors Act, The Living Organ Donor Tax Credit Act (H.R. 6171), and the Living Donor Protection Act (H.R. 2923/S. 1384) Increase patient choice by passing the Kidney PATIENT Act (H.R. 5074), the Restore Protections for Dialysis Patients Act (H.R. 6860), the Chronic Kidney Disease Research and Treatment Act, (H.R. 5027/S. 4469), and the Providing Relief and Stability for Medicare Patients Act of 2023 (H.R. 3674) Bolster the kidney health care workforce, including by passing the Healthcare Workforce Resilience Act (H.R. 6205/S. 3211), the Strengthening Medicare for Patients and Providers Act (HR 2474), The Specialty Physicians Advancing Rural Care Act (S. 705/ H.R. 2761), and the Resident Physician Shortage Act (HR 2389/S. 1302) Regulatory: Increase kidney health coordination, innovation, and reimbursement through CY24 ESRD PPS/QIP, CY24 PFS, and 2023 ESRD-QIP Measure Set Review Improve transparency and accountability in transplant system to maximize access to kidney transplant, including through the HRSA OPTN Modernization Initiative Establish a federal screening recommendation for kidney diseases

Client expense: $100,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

Treat and Reduce Obesity Act (H.R. 4818 / S. 4207) Home dialysis/home therapies issues Improving Access to Dialysis Act (H.R. 8075) Living Donor Protection Act (H.R. 2923/S. 1384) FY 2025 appropriations funding for nursing workforce development programs and National Institute of Nursing Research FY 2025 funding kidney disease research at NIDDK at NIH Funding for Kidney X program at HHS Funding for AHRQ at HHS in FY 2025 Securing the U.S. Organ Procurement and Transplantation Network Act (H.R. 2544/S. 1668) National Nursing Workforce Center Act (H.R. 2411/S. 1150) Workplace Violence Prevention for Health Care and Social Service Workers Act (H.R. 2663/S. 1176) Living Donor Protection Act (H.R. 2923/S. 1384) Chronic Kidney Disease Improvement in Research and Treatment Act (H.R. 5027) Kidney Patient Access to Technology Innovative and Essential Nephrology Treatments (Kidney Patient) Act (H.R. 5074) Restore Protections for Dialysis Patients Act (H.R. 6860) Living Organ Donor Tax Credit Act (H.R. 6171) Honor Our Living Donors Act (H.R. 6020) Healthcare Workforce Resilience Act (H.R. 6205 / S. 3211) Restore Protections for Dialysis Patients Act (H.R. 6860) Future Advancement of Academic Nursing Act (H.R. 7266 / S. 3770)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); H.R. 6860, Restore Protections for Dialysis Patients Act; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing End-Stage Renal Disease (ESRD) functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model (11/6/23)

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; H.R. 6860, the Restore Protections for Dialysis Patients Act; H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023; H.R. 5074/S. 4510, Kidney PATIENT Act of 2023

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 5074, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 S. 4469, A bill to improve the understanding of, and promote access to treatment for, chronic kidney disease, and for other purposes Issues related to patient access to infection prevention.

Client expense: $240,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Client expense: $260,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 6860, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,040,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 6860, Restore Protections for Dialysis Patients Act Issues related to End Stage Renal Disease (ESRD) Perspective Payment System (PPS) Issues related to nursing shortages CMS regulations pertaining to the Medicare Advantage program Issues related to home dialysis Issues related to chronic kidney disease (CKD) and prevention Issues related to access to kidney transplantation for ESRD patients ESRD Treatment Choices (ETC) mandatory demonstration Kidney Care Choices (KCC) Model and the Comprehensive Kidney Care Contracting (CKCC) voluntary payment options ESRD facilities serving as originating sites for telehealth services under the Medicare program H.R. 5074/S. 4510, the Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act

Client expense: $1,040,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; H.R. 6860, Restore Protections for Dialysis Patients Act; H.R. 5074 Kidney Patient Act of 2024; H.R. 5074/S. 4510 Kidney PATIENT Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Training Act; H.R. 6860, Restore Protections for Dialysis Patients Act; H.R. 5074 Kidney Patient Act of 2024; H.R. 5074/S. 4510 Kidney PATIENT Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 5027 - The Chronic Kidney Disease Improvement in Research and Treatment Act S. 377/H.R 1255 - The Living Donor Protection Act H.R. 6860 - The Restore Protections for Dialysis Patients Act H.R. 5074 - The Kidney PATIENT Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Urge Congress to provide access to Medigap for all ESRD patients under 65 years of age; Protect organ donors by urging passage of the living donor legislation; Protect dialysis patient access to charitable premium assistance; Support ESRD care coordination; Encourage support for improved kidney research and treatment; Support increased oversight of Organ Procurement Organizations; Support H.R. 5027/S. 4469 the Chronic Kidney Disease Improvement in Research and Treatment Act; Assist the Administration about prioritizing prevention of kidney disease and home dialysis; Support H.R. 6860 -The Restore Protections for Dialysis Patients Act to protect access to private insurance; Urge the Administration to provide adequate reimbursement to address the ongoing staffing shortages at dialysis centers; and Urge the Administration to provide appropriate reimbursement to increase dialysis patient access to new and innovative therapies. Urge passage of H.R. 5074/S. 4510 - The Kidney Patient Act that would delay the move of oral-only ESRD drugs into the ESRD bundle until 2033.

Client expense: $500,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, White House Office

Living Donor Protection Act (H.R. 2923 / S. 1384) Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027/S.4469) Honor Our Living Donors Act (H.R. 6020) Medigap Expansion Act Restore Protections for Dialysis Patients Act (H.R. 6860) Expressing support for the designation of the last Tuesday of April each year as "APOL1-Mediated Kidney Disease (AMKD) Awareness Day" (H.Res.1124) Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 (H.R. 5074, S. 4510) PASTEUR Act (H.R. 2940/S. 1355) Appropriations-NIH, NIDDK, Kidney Research The New Era for Preventing End-Stage Kidney Disease Act of 2023 The Access to Genetic Counselor Services Act of 2023 (H.R. 3876/S. 2323) The CARING for Social Determinants Act of 2023 (H.R. 1066) End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model

Client expense: $240,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare reform for dialysis patients; H.R.5027 - Chronic Kidney Disease Improvement in Research and Treatment Act; H.R.6860 - Restore Protections for Dialysis Patients Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE